MétaCan
Menu
Back to cohort

There is no upper limit on the maximum effect that can be detected in randomized trials

2025· article· en· W4410292011 on OpenAlexaff
Benjamin Djulbegović, Iztok Hozo, Renata Iskander, Austin Parish, Jonathan Kimmelman, John P. A. Ioannidis

Bibliographic record

VenueJournal of Clinical Epidemiology · 2025
Typearticle
Languageen
FieldMathematics
TopicAdvanced Causal Inference Techniques
Canadian institutionsMcGill UniversityMcGill University Health Centre
FundersNational Institute of Neurological Disorders and StrokeNational Cancer InstituteNational Institutes of Health
KeywordsRandomized controlled trialLimit (mathematics)MedicineInternal medicineMathematicsMathematical analysis

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVES: Randomized controlled trials (RCTs) are commonly viewed as essential for detecting small treatment benefits, yet they also identify large ("dramatic") effects. Forecasting the likelihood of future large effects helps guide resource allocation for conducting clinical trials. METHODS: We included consecutive cancer RCTs from 5 cohorts identified by funders or trial registries, minimizing publication bias. Between 1955 and 2018 (and published by 2022), 716 RCTs compared 984 experimental vs standard treatments in approximately 350,000 patients. We applied a generalized Pareto distribution (GPD) under Extreme Value Theory to predict future maximum treatment effects using data spanning 65 years. RESULTS: The GPD's positive shape parameter implies no upper limit on maximum treatment effects. Historically, the largest observed effect had an odds ratio (OR) of 45 (95% CI: 2-1008). If current patterns hold, the largest effect over the next 50 years is projected at OR = 23 (95% CI: 13-106). We estimated 20% probability of detecting new treatments with OR >50 within the same time frame. Increasing the number of RCTs from about 20 to 40 or 60 per year would double or triple the likelihood of detecting breakthrough treatments with dramatic effects. CONCLUSION: Our findings suggest there may be no absolute upper bound on discoverable treatment effects in cancer RCTs, although estimates will likely remain in the range observed between 1955 and 2022. Conducting more RCTs would boost the probability of identifying treatments with large effects, underscoring the importance of sustained or expanded trial activity to accelerate breakthrough discoveries. PLAIN LANGUAGE SUMMARY: New treatments cannot be discovered without individuals volunteering to participate in clinical studies. Among all types of human clinical studies, RCTs are considered the most reliable method for evaluating new medical treatments and are especially effective at detecting small beneficial effects. This study also demonstrates that conducting more RCTs would accelerate the discovery of treatments with both small and large effects. By increasing public participation in RCTs, we can drive faster advances in therapeutics and influence policy decisions to allocate more resources toward the conduct of these trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.376
metaresearch head score (Gemma)0.718
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: Theoretical or conceptual
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.624
Threshold uncertainty score0.770

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3760.718
Meta-epidemiology (narrow)0.0050.007
Meta-epidemiology (broad)0.0260.013
Bibliometrics0.0070.005
Science and technology studies0.0030.016
Scholarly communication0.0150.026
Open science0.0120.012
Research integrity0.0220.031
Insufficient payload (model declined to judge)0.0090.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.584
GPT teacher head0.593
Teacher spread0.009 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designTheoretical or conceptual
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractno

Explore more

Same venueJournal of Clinical EpidemiologySame topicAdvanced Causal Inference TechniquesFrench-language works237,207